MedChemExpress LLC (MCE)
  1. Companies
  2. MedChemExpress LLC (MCE)
  3. Products
  4. MedChemExpress - Model RBC8 - ...

MedChemExpressModel RBC8 - 361185-42-4

SHARE
RBC8 is a novel small molecule inhibitor of Ral GTPase; has IC50 of 3.
Most popular related searches

MCE products for research use only. We do not sell to patients.

RBC8

MCE China:RBC8

Brand:MedChemExpress (MCE)

Cat. No.HY-12873

CAS:361185-42-4

Purity:98.0%

Storage:Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year

Shipping:Room temperature in continental US; may vary elsewhere.

Description:RBC8 is a selective and allosteric RALA and RALB inhibitor. RBC8 stabilizes the inactive GDP-bound state of Ral, preventing its activation. RBC8 promotes the phosphorylation of proteins related to the MAPK/JNK pathway. RBC8 has the activity of inhibiting tumor cell proliferation, migration and invasion. RBC8 is used in the study of various cancers such as lung cancer, gastric cancer, and multiple myeloma.

In Vitro:RBC8 (10-20 μM; 3-72 h) can reduce the survival rate of myeloma cells AMO-1 and INA-6 and the level of RAL-GTP in sensitive INA-6 cells[1]. RBC8 (20 μM; 3 days of treatment) inhibits the colony formation of lung cancer cells H2122 and H358 in soft agar with IC50 of 3.5 μM and 3.4 μM, respectively[2]. RBC8 (20-40 μM) significantly inhibits the growth, migration and invasion of gastric cancer cell lines SGC-7901 and MGC-803[3].

In Vivo:RBC8 (50 mg/kg; i.p.; daily (except weekends); 21 days) inhibits tumor growth in nude mice inoculated with H2122 and H358 human lung cancer cells[2].

Hot selling product:Frexalimab  | 1-Bromo-4-(trifluoromethyl)benzene-d4  | PD-1/PD-L1-IN-9 (hydrochloride)  | ONC206  | SRT 2183  | Delamanid  | Cortisone  | EMD534085  | Glyphosate  | PFM08

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References:

[1]. Seibold M, et al. RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS. Haematologica. 2020 Sep 1;105(9):2316-2326.  [Content Brief]

[2]. Yan C, et al. Discovery and characterization of small molecules that target the GTPase Ral. Nature. 2014 Nov 20;515(7527):443-7.  [Content Brief]

[3]. Wang P, et al. RCC2 Interacts with Small GTPase RalA and Regulates Cell Proliferation and Motility in Gastric Cancer. Onco Targets Ther. 2020 Apr 14;13:3093-3103.  [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
•   It has a professional experimental center and strict quality control and verification system;
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
•   The biological activity of the products has been verified by the experiments of customers in various countries;
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。